Navigation Links
Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin
Date:8/16/2011

> bacteria to flourish. Older patients in particular are at risk for CDAD, potentially because of a weakened immune system or the presence of underlying disease. Approximately two-thirds of CDAD patients are 65 years of age or older.

Current estimates suggest CDAD may affect more than 700,000 people in the U.S. each year, though the incidence may be higher as many cases are believed to be undiagnosed, untreated and underreported. The disease adds significant costs and burden to the U.S. healthcare system with estimates for medical treatment and hospital stays associated with CDAD reaching as much as $3.8 billion every year. Historically, approximately 20% to 30% of CDAD patients who initially respond to treatment experience a clinical recurrence.

About Optimer

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has developed and commercialized DIFICID™ (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has filed a marketing authorization application with the European Medicines Agency for fidaxomicin. Optimer's clinical pipeline includes Pruvel™, a product in the fluoroquinolone class of antibiotics that has completed Phase 3 trials as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Forward Looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation statements related to DIFICID's ability to mitigate the impact of concomitant antibiotics on response to CDAD treatment. Words such as "believes", "would", "anticipates", "plans", "expects"
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... BOSTON , Aug. 29, 2014   Vittamed Corporation ... Boston announced today that T. (Teo) Forcht ... to the company,s Board of Directors. " ... distinguished career in neurosurgery, medical innovation and venture capital," said ... are extremely delighted to add his clinical, strategic, and entrepreneurial ...
(Date:8/29/2014)... Pa. , Aug. 29, 2014  Unilife Corporation ... UNS) announced today that it intends to release its ... year ended June 30, 2014 after market trading ends ... has scheduled a conference call for 4:30 p.m. U.S. ... 2014 at 6:30 a.m. AEST), to review the Company,s financial ...
(Date:8/29/2014)... , Aug. 29, 2014  In part four ... leverage a hospital pharmacy as a strategic asset, ... practice leader for Cardinal Health,s Innovation Delivery Solutions business, ... can benefit both hospitals and patients. "Every ... one part of their job in a value-based healthcare ...
Breaking Medicine Technology:Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4
(Date:9/2/2014)... Recently, Os-Monitor.com, an innovative company that provides many kinds ... employee internet monitoring products ( http://www.os-monitor.com ). Furthermore, the ... 10% off, on these useful items. , True ... different kinds of high end monitoring programs on its ... of all sizes. With its high end programs, the ...
(Date:9/2/2014)... Kicking blog MichaelHusted.com is featuring an interview ... role as a kicking coach, his kicking business, and on ... retired NFL kicker Michael Husted author of HustedKicking.com. , "Anthony ... one of the top pro free agent kickers out there,” ... at our 2014 Pro Camp and I was impressed with ...
(Date:9/2/2014)... simple awareness campaign in general practice identifies new cases ... ESC Congress today by Professor Jean-Marc Davy from France. ... most common cardiac arrhythmia. It multiplies the risk of ... stroke risk by five-fold. Similarly, AF is responsible for ... is often overlooked and diagnosed too late. In 20% ...
(Date:9/2/2014)... 2 September 2014: Health structures explain nearly 20% ... to the results of a joint ESC-OECD study ... Maggioni. Clinical variables explained more than 80% of ... unique evaluation which combines clinical data and health ... fuller picture of the reasons some patients with ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Developers and ... announced a new ProIntro Lesson from Pixel Film Studios. ... easy and fresh-looking titles,” said Christina Austin, CEO of ... armature, ProIntro is a definite game changer.” , Learn ... ProIntro Lesson from Pixel Film Studios. ProIntro is a ...
Breaking Medicine News(10 mins):Health News:Useful Employee Internet Monitoring Products Now For Sale At Os-Monitor.com 2Health News:MichaelHusted.com Features Interview with Anthony Cantele of Cantele Kicking on His Role as a Kicking Coach and on Becoming a National Camp Series (NCS) Associate 2Health News:MichaelHusted.com Features Interview with Anthony Cantele of Cantele Kicking on His Role as a Kicking Coach and on Becoming a National Camp Series (NCS) Associate 3Health News:Simple awareness campaign in general practice identifies new cases of AF 2Health News:Health structures explain nearly 20 percent of non-adherence to heart failure guidelines 2Health News:Pixel Film Studios Released a New ProIntro Lesson Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios Released a New ProIntro Lesson Exclusively for Final Cut Pro X 3
... new bladder cancer therapy show promising interim results. Lead ... drug Urocidin follows thirty years of his research in ... results of the trial," says Dr. Morales, professor emeritus ... director of the Queen,s University Centre for Applied Urological ...
... crashes each year. As a result, most states have put laws ... cell phones and PDAs while driving. But a new study led ... distracted driving and the laws being passed to address the problem. ... Journal of Preventive Medicine , is the first comprehensive collection and ...
... improve their outcomes if they walk briskly for at least ... recent study in Cancer Research , a journal of ... that men who walk briskly after their diagnosis may delay ... Erin Richman, Sc.D., a research associate at the University of ...
... MA May 24, 2010 CardioCareLive, the world,s ... Johns Hopkins University School of Medicine, today announced ... to be held over two days on Tuesday ... of interest to cardiovascular care and internal medicine ...
... 24, 2011 The latest episode in the ... Global Challenges/Chemistry Solutions ," focuses on new blood ... infected with an antibiotic-resistant bacterium that,s become a ... "superbug" is called methicillin-resistant Staphylococcus aureus, or simply ...
... , TUESDAY, May 24 (HealthDay News) -- Rain-making bacteria ... particles play in the Earth,s precipitation cycle, new research ... at the general meeting of the American Society for ... within the center of hailstones, suggesting that airborne microorganisms ...
Cached Medicine News:Health News:New made-in-Canada therapy for bladder cancer shows promising results 2Health News:Temple-led study finds widening gap between distracted driving and legislation 2Health News:Brisk walking could improve prostate cancer outcomes 2Health News:CME on atrial fibrillation, interventional cardiology and lipids online at CardioCareLive 2Health News:CME on atrial fibrillation, interventional cardiology and lipids online at CardioCareLive 3Health News:New American Chemical Society podcast: Fast test to diagnose MRSA infections 2Health News:Airborne Germs May Spur Rain, Snow, Hail 2
Pefakit TAFI Calibrators and Controls...
Plasma Control Level 2 - 1 ml...
... 1700 was developed to address hematology ... Ease of use, low maintenance, closed-tube ... reliability are features expected in the ... made fast access to results, sophisticated ...
Inquire...
Medicine Products: